-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
GreenLight Biosciences (NASDAQ:GRNA) and ITeos Therapeutics (NASDAQ:ITOS) Financial Contrast
GreenLight Biosciences (NASDAQ:GRNA) and ITeos Therapeutics (NASDAQ:ITOS) Financial Contrast
GreenLight Biosciences (NASDAQ:GRNA – Get Rating) and iTeos Therapeutics (NASDAQ:ITOS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.
Volatility & Risk
GreenLight Biosciences has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.
Get GreenLight Biosciences alerts:Analyst Recommendations
This is a breakdown of recent ratings and target prices for GreenLight Biosciences and iTeos Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
GreenLight Biosciences | 0 | 0 | 3 | 0 | 3.00 |
iTeos Therapeutics | 0 | 0 | 0 | 0 | N/A |
Valuation and Earnings
This table compares GreenLight Biosciences and iTeos Therapeutics' gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
GreenLight Biosciences | N/A | N/A | -$15.06 million | N/A | N/A |
iTeos Therapeutics | $344.77 million | 2.18 | $214.52 million | $6.88 | 3.08 |
iTeos Therapeutics has higher revenue and earnings than GreenLight Biosciences.
Profitability
This table compares GreenLight Biosciences and iTeos Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
GreenLight Biosciences | N/A | -195.71% | -45.30% |
iTeos Therapeutics | 57.48% | 42.62% | 31.39% |
Institutional & Insider Ownership
23.9% of GreenLight Biosciences shares are owned by institutional investors. Comparatively, 94.7% of iTeos Therapeutics shares are owned by institutional investors. 6.5% of iTeos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
iTeos Therapeutics beats GreenLight Biosciences on 8 of the 10 factors compared between the two stocks.
About GreenLight Biosciences
(Get Rating)
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
About iTeos Therapeutics
(Get Rating)
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for GreenLight Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GreenLight Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
GreenLight Biosciences (NASDAQ:GRNA – Get Rating) and iTeos Therapeutics (NASDAQ:ITOS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.
绿光生物(纳斯达克:GRNA-GET评级)和ITOS治疗(纳斯达克:ITOS-GET评级)都是小盘医疗公司,但哪只股票更优?我们将根据分析师的建议、盈利能力、风险、估值、机构所有权、股息和收益对这两家公司进行比较。
Volatility & Risk
波动性与风险
GreenLight Biosciences has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.
绿光生物科技的贝塔系数为1.33,这意味着其股价的波动性比标准普尔500指数高出33%。相比之下,iTeos Treateutics的贝塔系数为1.42,这意味着其股价的波动性比标准普尔500指数高42%。
Analyst Recommendations
分析师建议
This is a breakdown of recent ratings and target prices for GreenLight Biosciences and iTeos Therapeutics, as provided by MarketBeat.
这是由MarketBeat提供的绿光生物科学公司和iTeos治疗公司最近的评级和目标价格细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
GreenLight Biosciences | 0 | 0 | 3 | 0 | 3.00 |
iTeos Therapeutics | 0 | 0 | 0 | 0 | N/A |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
绿光生物科学 | 0 | 0 | 3 | 0 | 3.00 |
ITeos治疗公司 | 0 | 0 | 0 | 0 | 不适用 |
Valuation and Earnings
估值和收益
This table compares GreenLight Biosciences and iTeos Therapeutics' gross revenue, earnings per share (EPS) and valuation.
此表比较了Greenlight Biosciences和iTeos Treeutics的毛收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
GreenLight Biosciences | N/A | N/A | -$15.06 million | N/A | N/A |
iTeos Therapeutics | $344.77 million | 2.18 | $214.52 million | $6.88 | 3.08 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
绿光生物科学 | 不适用 | 不适用 | -1,506万元 | 不适用 | 不适用 |
ITeos治疗公司 | 3.4477亿美元 | 2.18 | 2.1452亿美元 | $6.88 | 3.08 |
iTeos Therapeutics has higher revenue and earnings than GreenLight Biosciences.
ITeos治疗公司的收入和收益高于绿光生物科学公司。
Profitability
盈利能力
This table compares GreenLight Biosciences and iTeos Therapeutics' net margins, return on equity and return on assets.
下表比较了绿光生物科学公司和iTeos治疗公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
GreenLight Biosciences | N/A | -195.71% | -45.30% |
iTeos Therapeutics | 57.48% | 42.62% | 31.39% |
净利润率 | 股本回报率 | 资产回报率 | |
绿光生物科学 | 不适用 | -195.71% | -45.30% |
ITeos治疗公司 | 57.48% | 42.62% | 31.39% |
Institutional & Insider Ownership
机构与内部人持股
23.9% of GreenLight Biosciences shares are owned by institutional investors. Comparatively, 94.7% of iTeos Therapeutics shares are owned by institutional investors. 6.5% of iTeos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
绿光生物科技23.9%的股份由机构投资者持有。相比之下,iTeos治疗公司94.7%的股份由机构投资者持有。ITeos治疗公司6.5%的股份由内部人士持有。强大的机构持股表明,捐赠基金、对冲基金和大型基金管理公司相信,一家公司的长期表现将好于大盘。
Summary
摘要
iTeos Therapeutics beats GreenLight Biosciences on 8 of the 10 factors compared between the two stocks.
ITeos治疗公司在两只股票之间的10个因素中有8个击败了绿光生物科学公司。
About GreenLight Biosciences
关于绿光生物科学
(Get Rating)
(获取评级)
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
绿光生物科技控股公司是一家生物技术公司,生产和销售用于人类健康和农业应用的核糖核酸(RNA)产品。它的人类健康产品包括信使核糖核酸疫苗和治疗药物,以及保护蜜蜂和农作物的农业核糖核酸产品。该公司成立于2008年,总部设在马萨诸塞州的梅德福德。
About iTeos Therapeutics
关于iTeos治疗公司
(Get Rating)
(获取评级)
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
ITeos治疗公司是一家临床阶段的生物制药公司,致力于为患者发现和开发免疫肿瘤疗法。该公司的产品线包括处于第二阶段临床试验的腺苷A2AR拮抗剂的小分子拮抗剂InupAdant,以及处于第1/2阶段临床试验的TIGIT或具有Ig和ITIM结构域的T细胞免疫受体拮抗剂EOS-448,以及用于激活树突状细胞和巨噬细胞并促进抗体依赖的细胞毒性或ADCC活性的Fc?R。ITeos治疗公司成立于2011年,总部设在马萨诸塞州沃特敦。
Receive News & Ratings for GreenLight Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GreenLight Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
获得《绿光生物科学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Greenlight Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧